Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The highly stereocontrolled de novo synthesis of l-NBDNJ (the unnatural enantiomer of the iminosugar drug Miglustat) and a preliminary evaluation of its chaperoning potential are herein reported. l-NBDNJ is able to enhance lysosomal α-glucosidase levels in Pompe disease fibroblasts, either when administered singularly or when coincubated with the recombinant human α-glucosidase. In addition, differently from its d-enantiomer, l-NBDNJ does not act as a glycosidase inhibitor.

Original publication

DOI

10.1021/acs.jmedchem.7b00646

Type

Journal article

Journal

J Med Chem

Publication Date

14/12/2017

Volume

60

Pages

9462 - 9469

Keywords

1-Deoxynojirimycin, Allosteric Regulation, Cell Line, Enzyme Activation, Enzyme Inhibitors, Fibroblasts, Glycogen Storage Disease Type II, Humans, Lysosomes, Models, Molecular, Stereoisomerism, alpha-Glucosidases